![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GC |
Gene summary for GC |
![]() |
Gene information | Species | Human | Gene symbol | GC | Gene ID | 2638 |
Gene name | GC vitamin D binding protein | |
Gene Alias | DBP | |
Cytomap | 4q13.3 | |
Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | P02774 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2638 | GC | S41 | Human | Liver | Cirrhotic | 1.46e-05 | -9.54e-01 | -0.0343 |
2638 | GC | S42 | Human | Liver | HCC | 7.42e-03 | -4.85e-01 | -0.0103 |
2638 | GC | S43 | Human | Liver | Cirrhotic | 6.46e-26 | -4.03e-01 | -0.0187 |
2638 | GC | S44 | Human | Liver | HCC | 2.81e-02 | -6.59e-01 | -0.0083 |
2638 | GC | HCC1_Meng | Human | Liver | HCC | 4.12e-31 | -1.56e-01 | 0.0246 |
2638 | GC | HCC2_Meng | Human | Liver | HCC | 2.71e-67 | -1.43e+00 | 0.0107 |
2638 | GC | cirrhotic2 | Human | Liver | Cirrhotic | 7.17e-07 | 2.86e-01 | 0.0201 |
2638 | GC | cirrhotic3 | Human | Liver | Cirrhotic | 1.28e-16 | -6.78e-01 | 0.0215 |
2638 | GC | p6 | Human | Liver | Cyst | 1.86e-19 | -1.48e+00 | -0.0218 |
2638 | GC | HCC1 | Human | Liver | HCC | 8.30e-06 | 3.63e+00 | 0.5336 |
2638 | GC | HCC2 | Human | Liver | HCC | 2.81e-27 | 6.74e+00 | 0.5341 |
2638 | GC | HCC5 | Human | Liver | HCC | 7.54e-16 | 3.23e+00 | 0.4932 |
2638 | GC | Pt13.a | Human | Liver | HCC | 2.71e-17 | -3.89e-01 | 0.021 |
2638 | GC | Pt13.b | Human | Liver | HCC | 6.04e-34 | -4.40e-01 | 0.0251 |
2638 | GC | Pt13.c | Human | Liver | HCC | 6.46e-04 | -5.40e-01 | 0.0076 |
2638 | GC | Pt14.a | Human | Liver | HCC | 2.30e-04 | -5.47e-01 | 0.0169 |
2638 | GC | Pt14.b | Human | Liver | HCC | 2.36e-08 | -3.18e-01 | 0.018 |
2638 | GC | Pt14.c | Human | Liver | HCC | 7.42e-04 | -7.82e-01 | 0.0054 |
2638 | GC | Pt14.d | Human | Liver | HCC | 1.58e-08 | -4.24e-01 | 0.0143 |
2638 | GC | S014 | Human | Liver | HCC | 2.61e-43 | -5.95e-01 | 0.2254 |
Page: 1 2 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006094 | Liver | NAFLD | gluconeogenesis | 20/1882 | 75/18723 | 3.52e-05 | 8.95e-04 | 20 |
GO:00060967 | Liver | NAFLD | glycolytic process | 21/1882 | 81/18723 | 3.58e-05 | 9.07e-04 | 21 |
GO:00067904 | Liver | NAFLD | sulfur compound metabolic process | 58/1882 | 339/18723 | 3.79e-05 | 9.38e-04 | 58 |
GO:00067577 | Liver | NAFLD | ATP generation from ADP | 21/1882 | 82/18723 | 4.37e-05 | 1.06e-03 | 21 |
GO:00106753 | Liver | NAFLD | regulation of cellular carbohydrate metabolic process | 31/1882 | 146/18723 | 4.47e-05 | 1.08e-03 | 31 |
GO:00083807 | Liver | NAFLD | RNA splicing | 70/1882 | 434/18723 | 4.62e-05 | 1.10e-03 | 70 |
GO:00100387 | Liver | NAFLD | response to metal ion | 62/1882 | 373/18723 | 5.05e-05 | 1.19e-03 | 62 |
GO:00160526 | Liver | NAFLD | carbohydrate catabolic process | 32/1882 | 154/18723 | 5.29e-05 | 1.21e-03 | 32 |
GO:00164825 | Liver | NAFLD | cytosolic transport | 34/1882 | 168/18723 | 5.52e-05 | 1.25e-03 | 34 |
GO:00338653 | Liver | NAFLD | nucleoside bisphosphate metabolic process | 28/1882 | 128/18723 | 5.89e-05 | 1.30e-03 | 28 |
GO:00338753 | Liver | NAFLD | ribonucleoside bisphosphate metabolic process | 28/1882 | 128/18723 | 5.89e-05 | 1.30e-03 | 28 |
GO:00340323 | Liver | NAFLD | purine nucleoside bisphosphate metabolic process | 28/1882 | 128/18723 | 5.89e-05 | 1.30e-03 | 28 |
GO:0000096 | Liver | NAFLD | sulfur amino acid metabolic process | 12/1882 | 34/18723 | 6.82e-05 | 1.45e-03 | 12 |
GO:00712145 | Liver | NAFLD | cellular response to abiotic stimulus | 56/1882 | 331/18723 | 7.01e-05 | 1.47e-03 | 56 |
GO:01040045 | Liver | NAFLD | cellular response to environmental stimulus | 56/1882 | 331/18723 | 7.01e-05 | 1.47e-03 | 56 |
GO:00718267 | Liver | NAFLD | ribonucleoprotein complex subunit organization | 42/1882 | 227/18723 | 7.21e-05 | 1.51e-03 | 42 |
GO:19033207 | Liver | NAFLD | regulation of protein modification by small protein conjugation or removal | 44/1882 | 242/18723 | 7.53e-05 | 1.56e-03 | 44 |
GO:00061104 | Liver | NAFLD | regulation of glycolytic process | 14/1882 | 45/18723 | 8.46e-05 | 1.72e-03 | 14 |
GO:00066943 | Liver | NAFLD | steroid biosynthetic process | 34/1882 | 173/18723 | 1.01e-04 | 2.02e-03 | 34 |
GO:00097437 | Liver | NAFLD | response to carbohydrate | 45/1882 | 253/18723 | 1.07e-04 | 2.11e-03 | 45 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GC | SNV | Missense_Mutation | c.1096A>G | p.Thr366Ala | p.T366A | P02774 | protein_coding | tolerated(0.35) | benign(0.093) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GC | SNV | Missense_Mutation | novel | c.1236G>T | p.Lys412Asn | p.K412N | P02774 | protein_coding | tolerated(0.22) | benign(0.04) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
GC | insertion | Frame_Shift_Ins | novel | c.41_42insTA | p.Arg14SerfsTer8 | p.R14Sfs*8 | P02774 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
GC | insertion | Nonsense_Mutation | novel | c.40_41insACATTTATTAAGCAGTATTCCATGGAATGGGGAATCAATTA | p.Arg14AsnfsTer4 | p.R14Nfs*4 | P02774 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
GC | SNV | Missense_Mutation | c.1112G>A | p.Arg371Lys | p.R371K | P02774 | protein_coding | deleterious(0.02) | benign(0.333) | TCGA-AA-3982-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
GC | SNV | Missense_Mutation | c.858G>T | p.Glu286Asp | p.E286D | P02774 | protein_coding | tolerated(1) | benign(0.005) | TCGA-AA-3982-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
GC | SNV | Missense_Mutation | c.860N>T | p.Ser287Phe | p.S287F | P02774 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
GC | SNV | Missense_Mutation | c.818N>A | p.Leu273Gln | p.L273Q | P02774 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AU-3779-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GC | SNV | Missense_Mutation | c.356C>A | p.Ser119Tyr | p.S119Y | P02774 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
GC | SNV | Missense_Mutation | rs746394990 | c.295G>C | p.Asp99His | p.D99H | P02774 | protein_coding | deleterious(0.02) | possibly_damaging(0.9) | TCGA-AG-A00Y-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2638 | GC | DRUGGABLE GENOME | inhibitor | CHEMBL712 | ANISINDIONE | |
2638 | GC | DRUGGABLE GENOME | cetuximab | CETUXIMAB | 29208668 | |
2638 | GC | DRUGGABLE GENOME | Isosorbide Dinitrate | |||
2638 | GC | DRUGGABLE GENOME | VITAMIN D | 761406 | ||
2638 | GC | DRUGGABLE GENOME | CHEMBL2105671 | AFEGOSTAT TARTRATE | ||
2638 | GC | DRUGGABLE GENOME | bevacizumab | BEVACIZUMAB | 29208668 | |
2638 | GC | DRUGGABLE GENOME | Pirsidomine | PIRSIDOMINE | ||
2638 | GC | DRUGGABLE GENOME | Erythrityl Tetranitrate | |||
2638 | GC | DRUGGABLE GENOME | ASA | ASPIRIN | 17555340 | |
2638 | GC | DRUGGABLE GENOME | Nitric Oxide |
Page: 1 2 |